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NeuroinﬂammationAbstract Prolonged exposure to an opioid induces hyperalgesia and tolerance, which negatively
affect pain management in turn and signiﬁcantly hamper the application of opioids. A growing
body of evidence has demonstrated that glial activation contributes to the development of these
two side effects. Recent studies have demonstrated that morphine, binding to an accessory protein
of Toll-like receptor 4 (TLR4), activates microglia and produces neuroinﬂammation in a
manner parallel to lipopolysaccharide. Meanwhile, lipopolysaccharide activates microglia through
TLR4/caspase signalling. Therefore, we hypothesise that morphine may activate microglia through
TLR4/caspase signalling and that caspase inhibitors may attenuate opioid-induced hyperalgesia
and tolerance via inhibiting microglial activation and neuroinﬂammation.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Opioids remain a class of powerful analgesics for the clinical
treatment of various forms of chronic pain (cancer or non-can-
cer), but side effects such as opioid-induced hyperalgesia and
tolerance signiﬁcantly hamper their application [1,2]. Opioid-
induced hyperalgesia and tolerance are closely related and
share overlapping mechanisms [3]. These two phenomena havertment of Anesthesiology, Union H
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niversity of Medical Sciences. Pub
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/j.jmhi.2012.11.002been attributed to a variety of neuronal mechanisms, including
the release of endogenous anti-opioid peptides such as
cholecystokinin, descending facilitation, internalisation and/
or desensitisation of opioid receptors, upregulation of
N-methyl-D-aspartate (NMDA) receptor function and so on
[4]. Despite decades of research into neuronal mechanisms,
their bases remain far from clear and these two side effects
are still prevalent. However, a substantial and growing bodyospital, Tongji Medical College, Huazhong University of Science and
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32 Z. Weng et al.of literature has demonstrated that glial activation contributes
to the development of opioid-induced hyperalgesia and
tolerance and glia may become a new target for drug
discovery [4].
Glial activation promotes opioid-induced hyperalgesia and
tolerance
Glial cells, including microglia and astrocytes, are necessary
for normal central nervous system (CNS) function. Neverthe-
less, over-activation of glia results in the production of inﬂam-
matory factors such as tumour necrosis factor-a (TNF-a),
interleukin-1b (IL-1b) and nitric oxide (NO), which excite
pain-responsive neurons [5]. Prolonged exposure to an opioid,
for example, morphine, activates glial cells and causes neuroin-
ﬂammation, which contribute to opioid-induced hyperalgesia
and tolerance [4]. This conclusion can be inferred from the fol-
lowing evidences: (a) morphine induces glial activation and the
release of pro-inﬂammatory cytokines and chemokines; (b)
glial-activation inhibitors such as ﬂuorocitrate, minocycline
and ibudilast (AV411) enhance morphine analgesia; and (c)
inhibitors of pro-inﬂammatory cytokine strengthen morphine
analgesia [6].
TLR4 is a key modulator in opioid-induced hyperalgesia and
tolerance
Toll-like receptors (TLRs) are a well-known family of pattern-
recognition receptors, which play critical roles in the innate im-
mune system by recognising invading microbes. TLR4 is pre-
dominantly expressed by microglia in the CNS. There are
strong evidences supporting the idea that morphine leads to
microglial activation via TLR4: (a) morphine binds to myeloid
differentiation protein-2 (MD-2), induces TLR4 oligomeri-
sation and stimulates TLR4 signalling, in a manner parallel
to LPS; and (b) many different types of techniques, including
RNA interference, genetic knockout and small-molecule inhib-
itors, are used to target and inactivate the TLR4/MD-2 com-
plex, and all of them inhibit morphine-induced microglial
activation [7]. Moreover, TLR4, excluding the classical opioid
receptor, is a key modulator in opioid-induced hyperalgesia
and tolerance: (a) opioid-induced hyperalgesia is still observed
in triple opioid receptor knockout mice; (b) TLR4 agonists
produce opioid-induced hyperalgesia and tolerance; and (c)
TLR4 antagonists or genetic knockout of TLR4 or its signal-
ling components have all demonstrated their ability to enhance
morphine analgesia [8,9].Caspases promote microglial activation in response to TLR4
ligand stimulation
Caspases (cysteinyl-aspartate-speciﬁc proteases), a family of
cysteine proteases, are essential in cells for apoptosis and
their roles are considered a commitment to cell death. Re-
cently, Burguillos et al. [10] reported that TLR4 ligation,
lipopolysaccharide (LPS), activates caspase 8, which in turn
activates caspase 3/7, and these three killer caspases can
activate microglia in the absence of death. This non-apopto-
tic caspase signalling causes neuroinﬂammation. Moreover,
Wang et al. [7] have found that morphine activates microgliaand produces neuroinﬂammation in a manner parallel to
LPS.
Hypothesis
On the basis of the above-mentioned ﬁndings, we hypothesise
that morphine promotes microglial activation via TLR4/cas-
pase signalling and that caspase inhibitors reduce opioid-in-
duced hyperalgesia and tolerance through attenuating
microglial activation and neuroinﬂammation.
Prolonged morphine exposure results in the activation of
caspase-3 and the apoptosis of microglia and neurons.[11,12]
The authors believed that caspase inhibitors prevented mor-
phine-induced hyperalgesia and tolerance by blocking mor-
phine-induced neuronal apoptosis [11]. However, they might
have overlooked the role of caspase inhibitors in inhibiting
microglial activation and neuroinﬂammation.
Evaluation of the hypothesis
We understand that morphine activates microglia in a manner
parallel to LPS from the following evidences: (a) morphine
binds to myeloid differentiation protein 2 (MD-2) and the
TLR4 accessory protein, induces TLR4/MD-2 oligomerisation
and activates subsequent TLR4 signalling; (b) morphine pro-
motes microglial activation through TLR4 apart from the clas-
sical opioid receptor; and (c) microglia is activated by
morphine solely through binding in a speciﬁc LPS-binding
pocket of MD-2, excluding an interaction along the intracellu-
lar signalling pathway of TLR4 [7]. In addition, LPS activates
microglia through TLR4/caspase signaling [10]. Consequently,
we can obtain the above hypothesis.
Caspases are cysteine proteases involved in apoptosis. They
are classiﬁed into two groups: upstream initiator caspases
(including caspases 1, 2, 4, 5, 8, 9, 10, 11 and 12) and downstream
executioner caspases (including caspases 3, 6, 7 and 14) [13]. Be-
cause caspase activation is related to apoptosis, synthetic cas-
pase inhibitors have been used as research tools, and they are
viewed as potential therapeutics targeting apoptosis in disease
[14]. However, not all caspases primarily mediate apoptosis.
For example, caspase-1 also plays an important role in im-
mune-mediated inﬂammation in some situation [7]. Caspases 8
and 3/7, commonly regarded as ‘executioner of apoptosis’, can
promote microglial activation in the absence of death [10]. Aras
et al. [15] reported that caspase activation facilitates astrogliosis
in the absence of cell death. Caspase inhibitors have been re-
ported to successfully prevent morphine-induced hyperalgesia
and tolerance in an animalmodel [11].However, one should also
remember that these two phenomena are also characterised by
reactive microgliosis and neuroinﬂammation.We speculate that
caspase inhibitors can reduce these two side effects via attenuat-
ing microglial activation and neuroinﬂammation.
Unexpectedly, although a global activation of caspases re-
sults in apoptosis, a growing number of studies indicate that
restricted and localised activation controls a multitude of phys-
iological conditions such as axon pruning, synaptic changes
that underlie memory and so on [13]. Thus, theoretical compli-
cations of inhibiting caspases may occur and thereby preclude
the application of caspase inhibitors. However, there exists a
cellular execution threshold of caspase activity that can distin-
guish normal controlled physiological processes from the
Figure 1 Diagrammatic representation of the hypothesis. Morphine may activate microglia through TLR4/caspase signaling and
caspase inhibitors may attenuate opioid-induced hyperalgesia and tolerance via inhibiting microglial activation and neuroinﬂammation.
Caspase inhibitors may attenuate opioid-induced hyperalgesia and tolerance via inhibiting 33irreversible phenotype of cell death, especially in Drosophila
melanogaster [16]. Furthermore, clinical trials are in progress.
PF-03491390 (pan-caspase inhibitor) signiﬁcantly decreases
serum aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels in patients with chronic hepatitis C
virus [17]; GS-9450 (selective caspase inhibitor) may be a
promising therapeutic drug in patients with non-alcoholic ste-
atohepatitis [18]. It seems likely that caspase inhibitors may be
a promising therapeutic drug in the future.
Testing the hypothesis
The following research directions are recommended to test our
hypothesis:
1. Rat models: (a) opioid-induced hyperalgesia is induced by
intrathecal injection of (+)-morphine, which activates
TLR4 signalling but has no l-opioid receptor activity [7];
and (b) opioid tolerance is induced by repeated intrathecal
injection of morphine.
2. Rats are randomly divided into four groups (n= 8 in each
group): sham, model, model plus vehicle, model plus cas-
pase inhibitors. Vehicle or caspase inhibitors are adminis-
tered intrathecally.
3. Thermal withdrawal latency and mechanical withdrawal
threshold are measured during the whole experimental
procedure.
4. At the end of the experiment, rats are euthanised and the
lumbosacral spinal cords are collected for further detections.
Test items include activation of caspases, glia activation
marker, nuclear factor jB (NFjB) p65 level, inﬂammatory
factors such as tumour necrosis factor-a (TNF-a), interleu-
kin-1b (IL-1b) and nitric oxide (NO).
5. Furthermore, we can verify the mechanisms in vitro. Cellu-
lar model: BV2 microglia cells are incubated with (+)-mor-
phine. Groups: model, model plus vehicle, model plus
TLR4 antagonists, model plus caspase inhibitors. Cell via-
bility and the above-mentioned test items are detected.
Conclusion and prospect
If our hypothesis is correct, morphine may activate microglia
and create neuroinﬂammation via the TLR4/caspase pathway,and caspase inhibitors may attenuate opioid-induced hyperal-
gesia and tolerance through decreasing microglial activation
and neuroinﬂammation. Recently, a newer, third-generation
broad-spectrum caspase inhibitor (quinolyl-valyl-O-methylas-
partyl-[-2,6-diﬂuorophenoxy]-methylketone) is noticed to have
the potential as a therapeutic compound, which can cross the
blood–brain barrier and appears to be far superior to zVAD-
fmk (pan-caspase inhibitor) in many respects, including greater
potency, selectivity, stability, cell permeability and lack of
toxicity [19]. We speculate that administration of caspase
inhibitors may be beneﬁcial in clinical treatment for opioid-in-
duced hyperalgesia and tolerance.Conﬂict of interest statement
None declared.Overview Box
What do we already know about the subject?
1. Morphine, binding to an accessory protein of TLR4,
activates microglia and produces neuroinﬂammation in a
manner parallel to lipopolysaccharide.
2. Lipopolysaccharide activates microglia through
TLR4/caspase signalling.
What does your proposed theory add to the current
knowledge available, and what beneﬁts does it have?
1. The hypothesis partly elucidates the pathophysio-
logical mechanisms involved in opioid-induced hyperalge-
sia and tolerance.
2. Caspase inhibitors may attenuate opioid-induced
hyperalgesia and tolerance via inhibiting microglial acti-
vation and neuroinﬂammation.
Among numerous available studies, what special further
study is proposed for testing the idea?
1. We can test the effect of caspase inhibitors in mor-
phine-induced hyperalgesia or tolerance animal model.
Test items include behavioural test, activation of caspases,
glia activation marker and inﬂammatory factors.
2. We can verify the mechanisms in vitro. Cell viability,
activation of caspases, glia activation marker and inﬂam-
matory factors are detected.
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